8-K: Aileron Therapeutics Appoints Interim CFO Following Departure of Charles Garner

Aileron Therapeutics has appointed Timothy M. Cunningham as interim chief financial officer, effective May 16, 2024, following the departure of Charles Garner.

Summary

• Aileron Therapeutics has appointed Timothy M. Cunningham as interim chief financial officer, effective May 16, 2024.
• This appointment follows the departure of Charles Garner from the CFO role on May 15, 2024.
• Mr. Cunningham will also serve as the company's principal financial officer and principal accounting officer.
• He is a consultant at Danforth Advisors, LLC, and will provide services under a consulting agreement.
• Aileron will pay Danforth an hourly rate for Mr. Cunningham's services and reimburse expenses.
• The consulting agreement can be terminated with 30 days' notice for cause or 60 days' notice without cause.
• Mr. Cunningham has extensive experience, including serving as CFO for Bionomics Limited and acting CFO for Peak Bio, Inc. and SAB Biotherapeutics, Inc.

Sentiment

Score: 6

Explanation: The announcement is neutral, indicating a change in personnel but not a significant positive or negative event. The company has acted quickly to fill the position, which is a positive sign.

Positives

• The company has quickly filled the CFO position with an experienced professional.
• Timothy M. Cunningham has a strong background in finance and life sciences.
• The consulting agreement provides flexibility for both the company and the consultant.
• Mr. Cunningham's experience includes serving as CFO for multiple public and private companies.

Negatives

• The departure of Charles Garner as CFO may create a period of transition.
• The interim nature of the appointment may introduce some uncertainty.

Risks

• The company may face challenges during the transition period with a new CFO.
• The consulting agreement could be terminated, requiring another CFO search.
• There is a risk of disruption to financial operations during the transition.

Management Comments

• Brian Windsor, Ph.D., President and Chief Executive Officer, signed the report on behalf of the company.

Industry Context

The appointment of an interim CFO is a common practice in the biotechnology industry when there is a sudden departure of a key executive. The use of consulting firms like Danforth Advisors is also common for interim roles, providing experienced professionals on a temporary basis.

Comparison to Industry Standards

• The use of a consulting firm for interim CFO services is a common practice in the biotech industry, with firms like Danforth Advisors specializing in providing experienced financial professionals to companies in transition.
• Many biotech companies, especially those in early stages, often rely on interim CFOs to manage their financial operations while they search for a permanent replacement.
• The 30-60 day termination clause in the consulting agreement is standard practice, providing flexibility for both parties.

Management Changes

Stakeholder Impact

• Shareholders may experience some uncertainty during the CFO transition.
• Employees may be affected by the change in leadership in the finance department.
• Creditors and suppliers may be monitoring the company's financial stability during this transition.

Key Dates

Keywords

CFO, Interim CFO, Chief Financial Officer, Aileron Therapeutics, Timothy M. Cunningham, Danforth Advisors, Executive Change, Financial Officer, Management Change